EMA Authorised: Striascan (ioflupane (123l)) — CIS bio international

View source ↗

Summary

The EMA authorised Striascan (ioflupane (123I)) from CIS bio international for radionuclide imaging in dementia and movement disorders, with the decision dated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia
• Movement Disorders

Drugs mentioned

• Striascan (ioflupane (123I))

Snippet

Status: Authorised. Therapeutic area: Radionuclide Imaging;Dementia;Movement Disorders. MAH: CIS bio international. Decision date: 24/04/2026